Anakinra (Kineret), a recombinant, nonglycosylated IL-1Ra that negatively regulates IL-1α and IL-1β, was used to treat patients with metastatic BC (NCT01802970); however, the results have not yet been published. Here, IL1B is linked to breast cancer.